SG Stocks

C8R.SI Stock Surges 8.7% in After-Hours Trading on May 5

Key Points

C8R.SI stock surged 8.7% to S$0.025 in after-hours trading on May 5, 2026.

Negative earnings, cash burn, and 56% revenue decline raise fundamental concerns.

Volume of 1.85M shares remained below average, suggesting weak conviction.

Meyka AI forecasts S$0.0269 by year-end 2026, but profitability turnaround remains uncertain.

Be the first to rate this article

Jiutian Chemical Group Limited (C8R.SI) gained 8.7% in after-hours trading on May 5, 2026, closing at S$0.025 on the Singapore Exchange (SES). The chemical manufacturer saw volume reach 1.85 million shares, below its average of 3 million. C8R.SI stock has struggled over the long term, down 96% from its peak, but today’s move signals renewed interest. The company manufactures dimethylformamide, methylamine, and other specialty chemicals for pharmaceutical and industrial markets. Investors tracking C8R.SI stock should monitor whether this bounce reflects genuine recovery or short-term volatility.

C8R.SI Stock Price Movement and Technical Setup

C8R.SI stock opened at S$0.024 and climbed to a day high of S$0.025, gaining 0.002 SGD from the previous close of S$0.023. The stock trades well below its 50-day average of S$0.02252 and 200-day average of S$0.02544, indicating a downtrend. Year-to-date, C8R.SI stock is down 4%, while the 52-week range spans S$0.018 to S$0.032.

Technical indicators show mixed signals. The RSI sits at 53.46, suggesting neutral momentum. The Money Flow Index (MFI) reads 69.83, indicating strong buying pressure despite low absolute prices. Bollinger Bands remain tight between S$0.02 and S$0.03, constraining volatility. Track C8R.SI on Meyka for real-time updates on price action and volume trends.

Fundamental Challenges and Financial Metrics

C8R.SI stock faces significant headwinds. The company posted a negative EPS of -S$0.02 and a PE ratio of -1.2, reflecting ongoing losses. Revenue per share stands at just S$0.0534, while net income per share is -S$0.083. The price-to-book ratio of 0.57 suggests the stock trades at a discount to book value, but this reflects depressed earnings.

Operating metrics reveal deeper problems. Free cash flow per share is -S$0.078, and operating cash flow per share is -S$0.065, both negative. The company’s return on equity (ROE) is -30.9%, and return on assets (ROA) is -23.6%. These metrics confirm Jiutian Chemical Group is burning cash and destroying shareholder value. The debt-to-equity ratio of 0.28 remains manageable, but profitability must improve for C8R.SI stock to recover.

Market Sentiment and Trading Activity

Volume on May 5 reached 1.85 million shares, representing 54% of the 30-day average. This below-average volume suggests the price move lacks conviction. The relative volume indicator (0.54) confirms weak participation, typical of penny stocks with thin liquidity.

Liquidation pressure remains a concern. The company’s market cap sits at S$47.7 million, making it highly vulnerable to large seller blocks. With 1.99 billion shares outstanding, each share represents minimal economic value. The current rally may attract short-term traders, but without fundamental improvement, C8R.SI stock risks reverting to lower levels. Meyka AI rates C8R.SI with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Growth Outlook and Price Forecasts

Meyka AI’s forecast model projects C8R.SI stock reaching S$0.0269 by year-end 2026, implying 7.6% upside from current levels. The three-year forecast stands at S$0.0311, and the five-year target is S$0.0352. These projections assume operational stabilization and modest revenue recovery. Forecasts are model-based projections and not guarantees.

Historical growth data paints a cautious picture. Revenue declined 56.4% year-over-year, while net income fell 11.6%. The company’s three-year revenue growth per share is -95.6%, indicating severe contraction. However, free cash flow growth improved 9.7% recently, suggesting potential stabilization. Earnings are scheduled to be announced on August 12, 2026, which could provide clarity on turnaround efforts.

Final Thoughts

C8R.SI stock’s 8.7% jump reflects tactical interest rather than fundamental recovery. While the price-to-book discount and modest debt load offer some appeal, negative earnings, cash burn, and collapsing revenue remain serious concerns. The stock trades at a fraction of its historical highs, and volume remains weak. Investors should wait for evidence of profitability before committing capital. The upcoming August earnings report will be critical. For now, C8R.SI stock remains a speculative play suited only for risk-tolerant traders monitoring turnaround catalysts. Conservative investors should avoid exposure until the company demonstrates sustainable profitability.

FAQs

Why did C8R.SI stock jump 8.7% today?

C8R.SI gained 8.7% to S$0.025 on May 5, 2026, with 1.85M shares traded below average volume. No specific catalyst announced; the rally likely reflects short-term speculative positioning or profit-taking.

Is C8R.SI stock a good buy at S$0.025?

C8R.SI faces significant headwinds: negative earnings, cash burn, and 56% revenue decline. The 0.57 price-to-book ratio appears cheap but reflects weak fundamentals. Meyka AI rates it HOLD; await profitability evidence.

What is Jiutian Chemical Group’s main business?

Jiutian Chemical manufactures specialty chemicals including dimethylformamide, methylamine, sodium hydrosulfite, and industrial methanol for pharmaceutical, electronics, textile, and agro-chemical industries. It also researches isotope technology.

What is the price target for C8R.SI stock?

Meyka AI projects C8R.SI at S$0.0269 by end-2026 (7.6% upside), S$0.0311 by 2029, and S$0.0352 by 2031, assuming operational stabilization and profitability turnaround.

When are C8R.SI earnings announced?

Jiutian Chemical announces earnings on August 12, 2026. This report is critical for assessing operational stabilization and profitability recovery, with potential stock price implications.

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.

What brings you to Meyka?

Pick what interests you most and we will get you started.

I'm here to read news

Find more articles like this one

I'm here to research stocks

Ask Meyka Analyst about any stock

I'm here to track my Portfolio

Get daily updates and alerts (coming March 2026)